



MEDICAL TIPS

DIABIZ Tablets

Issue XII, No. 45, 2023

Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

James S, et al. NEJM. 2023

- In patients with acute myocardial infarction (MI), therapies to further reduce the risk of adverse cardiovascular and metabolic outcomes are needed.
- Thus the effect of Dapagliflozin (10 mg) vs. placebo in patients without prior type 2 diabetes (T2DM) or chronic heart failure (HF), presenting with acute MI and impaired left ventricular (LV) systolic function was evaluated.
- Dapagliflozin resulted in a significant benefit in terms of cardiometabolic outcomes, with 34% and 20% more wins (vs. placebo) in the primary (death, hospitalization for HF, nonfatal MI, atrial fibrillation, T2DM, body weight decrease of $\geq 5\%$) and secondary (same as primary excluding body weight component) outcome respectively.
- Treatment with Dapagliflozin resulted in a lower incidence of new diagnosis of T2DM and a reduced mean body weight.

In patients with acute MI, treatment with Dapagliflozin resulted in significant benefits in terms of improvement in cardiometabolic outcomes.

